A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204

Trial Profile

A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Stannsoporfin (Primary)
  • Indications Hyperbilirubinaemia
  • Focus Adverse reactions
  • Acronyms JASMINE205
  • Sponsors InfaCare Pharmaceutical Corporation
  • Most Recent Events

    • 28 Feb 2018 Planned End Date changed from 1 Aug 2020 to 1 Apr 2020.
    • 28 Feb 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Apr 2020.
    • 15 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top